United Kingdom · 
What does Abingworth invest in?
Abingworth invests most often at Series B and Series A (55% of the rounds on record), in sectors such as Psychedelics, Bioimaging and Mrna.
Abingworth highlights
- 01
4 cheques in the last 12 months
- 02
Mostly Series B and Series A: 55% of its rounds
- 03
Sole investor in 6 rounds, median $15M
- 04
14 exits from the portfolio
What they do
Abingworth has helped young biopharma companies on both sides of the Atlantic turn the latest scientific discoveries into dozens of new treatments for patients.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $15M – $30M as they say
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- PsychedelicsBioimagingMrna
- Based in
- London, United Kingdom
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first75 appearances
- 2026
4 rounds
- Jul
- Jun
- May
- Mar
- 2025
2 rounds
- Apr
- Feb
- 2019
3 rounds
- Dec
- Dec
- May
- 2018
1 round
- Jun
- 2017
2 rounds
- Oct
- Jul
- 2015
3 rounds
- Jul
- Jul
- Apr
- 2014
4 rounds
- Jul
- May
- Apr
- Feb
- 2013
8 rounds
- Nov
- Oct
- Jul
- May
- Apr
- Feb
- Jan
- Jan
- 2012
4 rounds
- May
- May
- Mar
- Jan
- 2011
2 rounds
- Sept
- May
- 2010
3 rounds
- Nov
- Oct
- Oct
- 2009
9 rounds
- Nov
- Oct
- Oct
- Jul
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration20 named
ALAbingworth LlpManageriFiling they signed
CGChristina GibbsAuthorized Person of the GP of the GPiFiling they signed
DLDavid LeathersDirectoriFiling they signed
DLDavid LobeAuthorized Person of the GP of the GPiFiling they signed
EMElizabeth MuscarellaAuthorized Person of the GP of the GPiFiling they signed
GLGenghis Lloyd-HarrisExecutive OfficeriFiling they signed
IMIts Manager Abingworth LLPManageriFiling they signed
JAJames AbellExecutive OfficeriFiling they signed
JAJeremy AndersonAuthorized Person of the GP of the GPiFiling they signed
JHJohn HeardExecutive OfficeriFiling they signed
KHKenneth HaasPromoteriFiling they signed
KVKurt Von EmsterExecutive OfficeriFiling they signed
MAManager Abingworth LLPManageriFiling they signed
MBMichael BighamPromoteriFiling they signed
RRRob RosenAuthorized Person of the GP of the GPiFiling they signed
RRRobert RosenAuthorized Person of the GP of the GPiFiling they signed
SCShelley ChuPromoteriFiling they signed
SBStephen BuntingExecutive OfficeriFiling they signed
THTimothy HainesExecutive OfficeriFiling they signed
VMVincent MilesPromoteriFiling they signed
We also hold 27 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Who backs their funds
1 LP on record in Abingworth's funds
- Funds
- 1
The institutions that put money into its funds, which the firm then invests in companies.Source: an LP list.
Axon Partners Group1 fundFund Vintage Committed Abingworth - -
What they claim to have backed
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed14 in all
ProsensaBought by BioMarin Pharmaceutical$840MNov 2014
ProsensaListed$78MJun 2013
Portola PharmaceuticalsListed$100MMay 2013
Avila TherapeuticsBought by Celgene$350MJan 2012
IntellikineBought by Takeda Pharmaceutical$310MDec 2011
Clovis OncologyListed$130MNov 2011
Synosia TherapeuticsBought by Biotie Therapies$122MJan 2011
ZogenixListedUndisclosedNov 2010
Fovea PharmaceuticalsBought by Sanofi AventisUndisclosedOct 2009
Guava TechnologiesBought by Millipore$23MFeb 2009
AblynxListedUndisclosedNov 2007
Xenogen CorporationBought by Caliper Life SciencesUndisclosedFeb 2006
An exit counts when it came after the firm's first round in the company. From historical deal records.